Lazard Asset Management
ABCL icon

Lazard Asset Management’s AbCellera Biologics ABCL Stock Holding History

Lazard Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-305,224
Closed -$1.07M – 1936
2026
Q1 		$1.07M Sell
305,224
-23,493
-7% -$84.5K ﹤0.01% 1137
2025
Q4 		$1.12M Sell
328,717
-323,379
-50% -$1.44M ﹤0.01% 1118
2025
Q3 		$3.28M Buy
652,096
+142,302
+28% +$627K ﹤0.01% 707
2025
Q2 		$1.75M Sell
509,794
-323,368
-39% -$805K ﹤0.01% 1056
2025
Q1 		$1.86M Sell
833,162
-95,432
-10% -$274K ﹤0.01% 997
2024
Q4 		$2.72M Sell
928,594
-167,981
-15% -$468K ﹤0.01% 783
2024
Q3 		$2.85M Buy
1,096,575
+4,406
+0.4% +$12.2K ﹤0.01% 785
2024
Q2 		$3.23M Sell
1,092,169
-927,843
-46% -$3.51M ﹤0.01% 776
2024
Q1 		$9.15M Sell
2,020,012
-1,391,993
-41% -$7.1M 0.01% 555
2023
Q4 		$19.5M Buy
3,412,005
+265,172
+8% +$1.23M 0.02% 391
2023
Q3 		$14.5M Sell
3,146,833
-128,468
-4% -$782K 0.02% 464
2023
Q2 		$21.2M Buy
3,275,301
+32,102
+1% +$219K 0.03% 387
2023
Q1 		$24.5M Buy
3,243,199
+336,987
+12% +$3.06M 0.03% 359
2022
Q4 		$29.4M Sell
2,906,212
-378,810
-12% -$4.38M 0.04% 319
2022
Q3 		$32.5M Sell
3,285,022
-61,475
-2% -$674K 0.05% 296
2022
Q2 		$35.6M Buy
3,346,497
+156,660
+5% +$1.33M 0.05% 296
2022
Q1 		$31.1M Buy
3,189,837
+2,899,091
+997% +$27.4M 0.04% 366
2021
Q4 		$4.16M Buy
290,746
+149,738
+106% +$2.27M ﹤0.01% 806
2021
Q3 		$2.83M Buy
+141,008
New +$2.49M ﹤0.01% 866

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Lazard Asset Management's ABCL Position: Q2 2026 in Review

Lazard Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 305,224 shares — an estimated $1.07M sold.

Lazard Asset Management first reported a position in ABCL in Q3 2021 and held it in 19 quarters. The position peaked at $35.6M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Lazard Asset Management reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 305,224 AbCellera Biologics shares in Q2 2026, an estimated $1.07M.
  • Lazard Asset Management first reported a position in AbCellera Biologics in Q3 2021 and held it in 19 quarters.
  • Lazard Asset Management's AbCellera Biologics position peaked at $35.6M in Q2 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.